Oncotarget

Research Papers:

Upregulation of COL6A1 is predictive of poor prognosis in clear cell renal cell carcinoma patients

Fangning Wan, Hongkai Wang, Yijun Shen, Hailiang Zhang, Guohai Shi, Yao Zhu, Bo Dai and Dingwei Ye _

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:27378-27387. https://doi.org/10.18632/oncotarget.4860

Metrics: PDF 1805 views  |   HTML 3005 views  |   ?  


Abstract

Fangning Wan1,2,*, Hongkai Wang1,2,*, Yijun Shen1,2, Hailiang Zhang1,2, Guohai Shi1,2, Yao Zhu1,2, Bo Dai1,2, Dingwei Ye1,2

1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China

2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China

*These authors have contributed equally to this work

Correspondence to:

Dingwei Ye, e-mail: [email protected]

Keywords: COL6A1, clear cell renal cell carcinoma, prognosis, tumorigenesis

Received: May 08, 2015     Accepted: July 27, 2015     Published: August 07, 2015

ABSTRACT

Background: The extracellular matrix (ECM) is reported to play an important role in tumorigenesis and progression. Collagen VI is an important ECM protein. In this study, we investigated the potential role of the COL6A1 gene, which encodes the α1 polypeptide of collagen VI, in the biological functions involved in the progression and outcome of clear cell renal cell carcinoma (ccRCC).

Materials and methods: A total of 288 ccRCC patients who underwent radical nephrectomy (RN) or nephron sparing nephrectomy (NSS) at Fudan University Shanghai Cancer Center (FUSCC) were enrolled. Total RNA was extracted from frozen samples obtained from the tissue bank of FUSCC and expression of COL6A1 was determined by qRT-PCR. The clinical relationship between COL6A1 expression and ccRCC prognosis was analyzed. These data were then validated in the Cancer Genome Atlas (TCGA) cohort. We also investigated the effect of COL6A1 overexpression in a xenografted tumor model in nude mice in vivo.

Results: In multivariate analysis of TCGA cohorts, COL6A1 high expression was predictive of poor prognosis in ccRCC patients’ overall survival (OS) (HR: 2.588 95%CI 1.616–4.146) and disease free survival(DFS) (HR: 3.106 95%CI 1.534–6.288). In FUSCC cohorts, after adjusted for relevant factors, the COL6A1 expression indicates poor prognosis in ccRCC patients's OS (HR 2.211; 95% CI, 1.360–8.060) and DFS (HR 3.052; 95%CI, 1.500–6.210). COL6A1 overexpression promoted tumor growth in xenografted nude mice.

Conclusion: Increased COL6A1 expression correlates with poor prognosis in ccRCC patients. Moreover, COL6A1 stimulates tumor growth in vivo.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4860